Journal Specialty Index
Oncology
| Topic | Issue |
| Management of Third-Generation Target Therapy Resistance in Adenocarcinoma of the Lung | OCTOBER 2024 • VOL. 16 • NO. 10 |
| Latest Survival Outcomes for Lung Cancer in Hong Kong: A Focus on Advanced Stages and Novel Treatments | OCTOBER 2024 • VOL. 16 • NO. 10 |
| Lung Cancer Screening by Computed Tomography and Incidental Subcentimetre Lung Nodules on CT Images | OCTOBER 2024 • VOL. 16 • NO. 10 |
| Antibody-Drug Conjugates as a New Frontier for Metastatic Triple-Negative Breast Cancer | JULY 2024 • VOL. 16 • NO. 7 |
| Enhancing Advanced Renal Cell Carcinoma Outcomes With Adjuvant Immunotherapy | JULY 2024 • VOL. 16 • NO. 7 |
| Targeted Therapy for the Management of Pancreatic Cancer | JULY 2024 • VOL. 16 • NO. 7 |
| Current Treatment Landscape and Future Directions of Immunotherapy for Urothelial Carcinoma | JULY 2024 • VOL. 16 • NO. 7 |
| Clinical Unmet Needs of Patients With Gastroenteropancreatic Neuroendocrine Tumours in Hong Kong | DECEMBER 2023 • VOL. 15 • NO. 11 |
| Immunotherapy Regimens for Advanced Hepatocellular Carcinoma: Current Status and Future Perspectives | DECEMBER 2023 • VOL. 15 • NO. 11 |
| Prevention of Anal Cancers: The ANCHOR Trial Results and Implications for Clinical Care | NOVEMBER 2023 ‧ VOL. 15 ‧ NO. 10 |
| HPV-Associated Oropharyngeal Cancer in Hong Kong: How Distinct Is It? Could It Be the Next Epidemic Disease in Our Locality? | NOVEMBER 2023 ‧ VOL. 15 ‧ NO. 10 |
| A Snapshot of the Human Papillomavirus | NOVEMBER 2023 ‧ VOL. 15 ‧ NO. 10 |
| Adjuvant Abemaciclib Shows Deepening Disease-Free Survival Benefits in High-Risk HR+, HER2-, Node-Positive Early Breast Cancer | JUNE 2023 ‧ VOL. 15 ‧ NO. 4 |
| A New Paradigm Shift in NSCLC Treatment – Neoadjuvant Immunotherapy Plus Chemotherapy | JUNE 2023 ‧ VOL. 15 ‧ NO. 4 |
| Optimising mCRPC Management With Genetic Testing | JUNE 2023 ‧ VOL. 15 ‧ NO. 4 |
| Adjuvant Immunotherapy Options for Early Non-Small Cell Lung Cancer | JUNE 2023 ‧ VOL. 15 ‧ NO. 4 |
| Gastric Cancer Screening | MAY 2023 ‧ VOL. 15 ‧ NO. 3 |
| An Update on Current State-Of-The-Art Investigative Modalities for the Small Bowel | MAY 2023 ‧ VOL. 15 ‧ NO. 3 |
| A Review on the Role of Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma | MAY 2023 ‧ VOL. 15 ‧ NO. 3 |
| Targeted Approach to Optimise Treatment for GEP-NETs After Early Progression | NOVEMBER 2022 ‧ VOL. 14 ‧ NO. 10 |
| Immunotherapy as First-Line Treatment for Unresectable Metastatic MSI-H/dMMR Colorectal Cancer | NOVEMBER 2022 ‧ VOL. 14 ‧ NO. 10 |
| Olaparib Plus Bevacizumab Provides an Overall Survival Benefit for Patients With Advanced HRD+ Ovarian Cancer | NOVEMBER 2022 ‧ VOL. 14 ‧ NO. 10 |
| Urothelial Cancer: Burden of Disease and Treatment Paradigm | NOVEMBER 2022 ‧ VOL. 14 ‧ NO. 10 |
| Lung Cancer Patients With No EGFR Mutation. Eligible for Oral Targeted Therapy? | SEPTEMBER 2022 ‧ VOL. 14 ‧ NO. 8 |
| "I've HER2 There Was a Secret Chord": Antibody-Drug Conjugates for Breast Cancer | JUNE 2022 ‧ VOL. 14 ‧ NO. 5 |
| Advanced but Less Lethal: ALK-Targeted Therapy for Non-small Cell Lung Cancer | JUNE 2022 ‧ VOL. 14 ‧ NO. 5 |
| Advanced Gastric Cancer: Current Treatment Landscape | JUNE 2022 ‧ VOL. 14 ‧ NO. 5 |
| The Long Game on Non-small Cell Lung Cancer: 5-Year Updates From the PACIFIC Trial | JUNE 2022 ‧ VOL. 14 ‧ NO. 5 |
| Novel Faecal Bacterial Markers for Colon Cancer and Polyp Detection | MARCH 2022 ‧ VOL. 14 ‧ NO. 2 |
| Age Strategy for Colorectal Cancer Screening in Average-Risk Populations: Insights From US Recommendations | MARCH 2022 ‧ VOL. 14 ‧ NO. 2 |
| Two Sex-Specific Cancers, One Targeted Therapy: Review of the Use of a PARP Inhibitor in Advanced Prostate and Ovarian Cancers | NOVEMBER 2021 ‧ VOL. 13 ‧ NO. 8 |
| Understanding Bone Metastases and Their Management | NOVEMBER 2021 ‧ VOL. 13 ‧ NO. 8 |
| Immunotherapy - First-Line Standard of Care for Advanced Non-small Cell Lung Cancer Treatment in Hong Kong | NOVEMBER 2021 ‧ VOL. 13 ‧ NO. 8 |
| Disseminated Mycobacterium szulgai Infection Mimicking Lung Cancer | NOVEMBER 2021 ‧ VOL. 13 ‧ NO. 8 |
| Update on the Use of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Thrombosis | SEPTEMBER 2021 ‧ VOL. 13 ‧ NO. 7 |
| Turning Theory Into Action: Integrating Clinical Data With Real-World Evidence in Breast Cancer Treatment | JUNE 2021 ‧ VOL. 13 ‧ NO. 6 |
| Updates in the Management of Advanced Endometrial Cancer | JUNE 2021 ‧ VOL. 13 ‧ NO. 6 |
| Sequence Makes a Difference: Maximizing the Potential PFS Gains With Ramucirumab Plus Erlotinib in EGFR-Positive NSCLC | JUNE 2021 ‧ VOL. 13 ‧ NO. 6 |
| Early Access to Dacomitinib for First-Line EGFR Mutation-Positive Non-Small Cell Lung Cancer Patients | JUNE 2021 ‧ VOL. 13 ‧ NO. 6 |
| Diagnosis for Lung Cancer: CT Guided, Endobronchial Ultrasound or Electromagnetic Navigation? | MAY 2021 ‧ VOL. 13 ‧ NO. 5 |
| Oral Contraceptives, Hormone Replacement Therapy and Breast Cancer Risk | APRIL 2021 ‧ VOL. 13 ‧ NO. 4 |
| 40 Years of Endoscopic Ultrasound | FEBRUARY 2021 ‧ VOL. 13 ‧ NO. 2 |
| Antibody-Drug Conjugate: A Rising HER2- Targeted Therapy for Multiple Solid Cancers | AUGUST 2020 ‧ VOL. 12 ‧ NO. 7 |
| New Frontiers in Breast Cancer Management | JUNE 2020 ‧ VOL. 12 ‧ NO. 6 |
| Targeting Mismatch Repair Defects with Immune Checkpoint Inhibitors as the First Tumour- Agnostic Cancer Treatment | JUNE 2020 ‧ VOL. 12 ‧ NO. 6 |
| Personalized Treatment of Metastatic Colorectal Cancer by Tumour Sidedness | JUNE 2020 ‧ VOL. 12 ‧ NO. 6 |
| Chemotherapy or Hormonal Therapy for Metastatic Castration-Resistant Prostate Cancer? | JUNE 2020 ‧ VOL. 12 ‧ NO. 6 |
| Oral Targeted Therapy, Can It Be More Durable in the Treatment of Lung Cancer in Asian Patients? | MAY 2020 ‧ VOL. 12 ‧ NO. 5 |
| Cancer-Associated Thrombosis Treatment Decision Pathway | JANUARY 2020 ‧ VOL. 12 ‧ NO. 1 |
| Serrated Lesions in Colorectal Cancer Screening | JANUARY 2020 ‧ VOL. 12 ‧ NO. 1 |
| Genetic Versus Genomic Testing in Cancer Management | NOVEMBER 2019 ‧ VOL. 11 ‧ NO. 8 |
| Cardio-oncology - Where Breast Cancer and Cardiovascular Disease Intersect | JULY 2019 ‧ VOL. 11 ‧ NO. 5 |
| Precision Medicine and Cancer Prevention - A Time of Transformation | MAY 2019 ‧ VOL. 11 ‧ NO. 4 |
| What are the Consequences in not Performing Endobronchial Ultrasound (EBUS)? | MAY 2019 ‧ VOL. 11 ‧ NO. 4 |
| First-line Treatment of Metastatic Non Small-Cell Lung Cancer with Immunotherapy Monotherapy | MARCH 2019 ‧ VOL. 11 ‧ NO. 2 |
| Immune-related Adverse Event of Cancer Immunotherapy | MARCH 2019 ‧ VOL. 11 ‧ NO. 2 |
| Colorectal Cancer Screening: Evidence and Emerging Issues | JANUARY 2019 ‧ VOL. 11 ‧ NO. 1 |
| Update on the Management of Adult Acute Lymphoblastic Leukaemia | SEPTEMBER 2018 ‧ VOL. 10 ‧ NO. 6 |
| A Step Forward for the Management of Patients with Follicular Lymphoma? | SEPTEMBER 2018 ‧ VOL. 10 ‧ NO. 6 |
| Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agent (Venetoclax) | SEPTEMBER 2018 ‧ VOL. 10 ‧ NO. 6 |
| Lung Cancer and Immuno-Oncology in 2018 | MAY 2018 ‧ VOL. 10 ‧ NO. 4 |
| Complete Response to Bevacizumab and Chemotherapy in an Elderly Patient with Metastatic Colorectal Cancer | JANUARY 2018 ‧ VOL. 10 ‧ NO. 1 |
| Curing Blood Cancers: No More Chemotherapy | NOVEMBER 2017 ‧ VOL. 9 ‧ NO. 7 |
| Good's Syndrome: An Acquired Immunodeficiency Associated with Thymomas | SEPTEMBER 2017 ‧ VOL. 9 ‧ NO. 6 |
| Osimertinib: A New Weapon Against the Acquired Resistance Mutation EGFR T790M in Non-small Cell Lung Cancer | MAY 2017 ‧ VOL. 9 ‧ NO. 4 |
| Endobronchial Ultrasound (EBUS) for Assessing the Suitability of Biologics and Immunotherapy in Lung Cancer | MAY 2017 ‧ VOL. 9 ‧ NO. 4 |
| Lung Cancer in the Young and Nonsmokers | MAY 2017 ‧ VOL. 9 ‧ NO. 4 |
| Exploring a New Era of Second-line NSCLC Treatment | JANUARY 2017 ‧ VOL. 9 ‧ NO. 1 |
| Blood Cancers: No More Chemotherapy? | NOVEMBER 2016 ‧ VOL. 8 ‧ NO. 7 |
| Lung Cancer - Q & A | MARCH 2016 ‧ VOL. 8 ‧ NO. 3 |
| Hodgkin Lymphoma and Use of Brentuximab Vedotin in its Treatment | JANUARY 2016 ‧ VOL. 8 ‧ NO. 1 |
| Lymphoma: New Age, New Drugs, New Survival | NOVEMBER 2015 ‧ VOL. 7 ‧ NO. 6 |
| Medical Nutrition Therapy for Cancer Cachexia Patients | JANUARY 2015 ‧ VOL. 7 ‧ NO. 1 |
| Personalized Treatments for Metastatic Colorectal Cancer | JUNE 2014 ‧ VOL. 6 ‧ NO. 3 |
| EGFR-Negative: Can I Use Oral Targeted Therapy? | JANUARY 2014 ‧ VOL. 6 ‧ NO. 1 |
| Role of Chemotherapy in Soft Tissue Sarcoma | MARCH 2012 ‧ VOL. 4 ‧ NO. 2 |
| Treatment of Metastatic Colorectal Carcinoma | DECEMBER 2011 ‧ VOL. 3 ‧ NO. 7 |
| Management of Early-stage Breast Cancer | MAY 2011 ‧ VOL. 3 ‧ NO. 3 |
| Targeted Therapy in Non-small Cell Lung Cancer | DECEMBER 2010 ‧ VOL. 2 ‧ NO. 8 |
| Colon Cancer - The Rising Star | NOVEMBER 2010 ‧ VOL. 2 ‧ NO. 7 |
| Clinical Evidence of the Quadrivalent HPV Vaccine in Adult Women over 26 | MAY 2010 ‧ VOL. 2 ‧ NO. 3 |
| Recent Advances in Cancer Treatment | JANUARY 2010 ‧ VOL. 2 ‧ NO. 1 |
| Towards Earlier Diagnosis of Lung Cancer | JANUARY 2010 ‧ VOL. 2 ‧ NO. 1 |
| Towards Earlier Diagnosis of Lung Cancer | DECEMBER 2009 ‧ VOL. 1 ‧ NO. 6 |
| Advances in Oncology 2009 | DECEMBER 2009 ‧ VOL. 1 ‧ NO. 6 |
Journal DEC 2024
Journal NOV 2024
Journal OCT 2024
Journal SEP 2024
